To ascertain the therapeutic potential of targeting NHE1 pathway in AML, the effects of FLT3, BTK, and CDK4 inhibition in combination with NHE1 inhibitor and KD were evaluated. This evidence concerns the gene SLC9A1 and acute myeloid leukemia.